Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 4/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | ITGB3 | P05106 | 6/20 | 0.54 |
| ▸ | ITGAV | P06756 | 6/20 | 0.54 |
| ▸ | EEF2K | O00418 | 3/20 | 0.52 |
| ▸ | ATM | Q13315 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | OGT | O15294 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7144205 | 0.89 | EEF2K (0.64) | POLBITGB3ITGAVEEF2KATM | |
| SCHEMBL3834077 | 0.87 | ALDH1A1 (0.50) | HTR6POLBITGB3ITGAVATM | |
| SCHEMBL7408745 | 0.82 | ITGB3 (0.67) | ITGB3ITGAVEEF2KATML3MBTL1 | |
| SCHEMBL23795546 | 0.81 | POLB (0.47) | HTR6POLBITGB3ITGAVALDH1A1 | |
| SCHEMBL31026026 | 0.81 | POLB (0.47) | HTR6POLBITGB3ITGAVALDH1A1 | |
| SCHEMBL23795545 | 0.81 | POLB (0.47) | HTR6POLBITGB3ITGAVALDH1A1 | |
| SCHEMBL6366667 | 0.81 | ITGB3 (0.60) | ITGB3ITGAVEEF2KATML3MBTL1 | |
| SCHEMBL14501730 | 0.81 | ITGB3 (0.53) | ITGB3ITGAVATML3MBTL1ALDH1A1 | |
| SCHEMBL7786198 | 0.80 | ITGB3 (0.49) | ITGB3ITGAVEEF2KATML3MBTL1 | |
| SCHEMBL7790169 | 0.79 | ITGB3 (0.49) | ITGB3ITGAVATMALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1235595-B8 | INTEGRIN-MEDIATED DRUG TARGETING | BAYER SCHERING PHARMA AG (DE) | 2009-10-07 | — | — | EP | disclosed |
| US-7220824-B1 | Integrin-mediated drug targeting | BAYER AKTIENGESELLSCHAFT (DE) | 2007-05-22 | — | — | US | disclosed |
| US-7220824-B1 | Integrin-mediated drug targeting | BAYER AKTIENGESELLSCHAFT (DE) | 2007-05-22 | — | — | US | disclosed |
| US-7220824-B1 | Integrin-mediated drug targeting | BAYER AKTIENGESELLSCHAFT (DE) | 2007-05-22 | — | — | US | disclosed |
| US-20060189544-A1 | Integrin-Mediated drug targeting | BAYER AKTIENGESELLSCHAFT (DE) | 2006-08-24 | — | — | US | disclosed |
| EP-1235595-A2 | INTEGRIN-MEDIATED DRUG TARGETING | Bayer Aktiengesellschaft (DE) | 2002-09-04 | — | — | EP | disclosed |
| WO-2001017563-A2 | INTEGRIN-MEDIATED DRUG TARGETING | BAYER AKTIENGESELLSCHAFT (DE) | 2001-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189544-A1 | Integrin-Mediated drug targeting | ITGAV, ITGB3, ITGB1 | HTR6 3134/4885POLB 3650/4885ITGB3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.